Physician profile
Timothy D Dibble
NPI 1023065232
$6,565.35
in general payments reported to CMS, 2019-2025
31 companies · $581 in 2025
The $581 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $39.59 · 2021: $1,678 · 2022: $1,262 · 2023: $1,438 · 2024: $1,147 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,166.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,205.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $763.81 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $665.75 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $651.21 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $510.01 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $486.09 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $388.47 | 2019-2025 | |
| Lilly USA, LLC | $263.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.44 | 2019-2024 | Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.71 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Glaxosmithkline, LLC. | $154.18 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $139.09 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $129.17 | 2019-2022 | |
| Amarin Pharma, INC. | $102.42 | 2021 | |
| Abbott Laboratories | $101.43 | 2024-2025 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $99.38 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $74.71 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $45.10 | 2021 | |
| Eisai INC. | $40.25 | 2021 | |
| Arbor Pharmaceuticals, INC. | $32.67 | 2021 | |
| Paratek Pharmaceuticals, INC. | $30.86 | 2024 | Nuzyra |
| Nabriva Therapeutics, Plc | $29.89 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.56 | 2021-2024 | |
| Axsome Therapeutics, INC. | $25.42 | 2023 | Auvelity |
| Sumitomo Pharma America, INC. | $23.05 | 2023 | Gemtesa |
| Dexcom, INC. | $17.18 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.84 | 2022 | |
| Currax Pharmaceuticals LLC | $14.81 | 2023 | Nexletol, Contrave, Nexlizet |
| Astellas Pharma US INC | $13.95 | 2019 | |
| Merck Sharp & Dohme LLC | $13.11 | 2021 | |
| Idorsia Pharmaceuticals US INC | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Dibble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.